Table 1.
Baseline characteristics of the enrolled patients.
| Enrolled Patients (n = 18) | |
|---|---|
| Sex (female) | 15 (83.3) |
| Age (years) | 47 (42–57) |
| Body mass index (kg/m2) | 21.5 (18.2–23.1) |
| Disease duration (years) | 6 (1–17) |
| Raynaud’s phenomenon duration (years) | 9 (4–17) |
| Smoking history (current or ex-) | 3 (16.7) |
| Interstitial lung disease | 10 (55.6) |
| Types of cutaneous manifestations | |
| Diffuse | 8 (44.4) |
| Limited | 10 (55.6) |
| Pulmonary hypertension | 1 (5.6) |
| History of renal crisis | 1 (5.6) |
| Hand dominance (right) | 18 (100.0) |
| Medical history | |
| Diabetes mellitus | 0 (0.0) |
| Hypertension | 0 (0.0) |
| Osteoporosis | 6 (33.3) |
| Medication status | |
| Calcium channel blocker | 9 (50.0) |
| Prostacyclin | 2 (11.1) |
| Alprostadil | 3 (16.7) |
| Endothelin receptor antagonist | 1 (5.6) |
| Azathioprine | 5 (27.8) |
| Glucocorticoid | 13 (72.2) |
| Methotrexate | 8 (44.4) |
| Ant-nuclear antibody | 18 (100.0) |
| Anti-centromere antibody | 4 (22.2) |
| Anti-Scl70 antibody | 13 (72.2) |
| Anti-Ro/SSA antibody | 4 (22.2) |
| Anti-U1 RNP antibody | 5 (27.8) |
Data are shown as n (%) or median (interquartile range).